Literature DB >> 33483222

Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).

Elizabeth A Evans1, Thomas J Stopka2, Ekaterina Pivovarova3, Sean M Murphy4, Faye S Taxman5, Warren J Ferguson6, Dana Bernson7, Claudia Santelices8, Kathryn E McCollister9, Randall Hoskinson10, Thomas Lincoln10, Peter D Friedmann11.   

Abstract

A major driver of the U.S. opioid crisis is limited access to effective medications for opioid use disorder (MOUD) that reduce overdose risks. Traditionally, jails and prisons in the U.S. have not initiated or maintained MOUD for incarcerated individuals with OUD prior to their return to the community, which places them at high risk for fatal overdose. A 2018 law (Chapter 208) made Massachusetts (MA) the first state to mandate that five county jails deliver all FDA-approved MOUDs (naltrexone [NTX], buprenorphine [BUP], and methadone). Chapter 208 established a 4-year pilot program to expand access to all FDA-approved forms of MOUD at five jails, with two more MA jails voluntarily joining this initiative. The law stipulates that MOUD be continued for individuals receiving it prior to detention and be initiated prior to release among sentenced individuals where appropriate. The jails must also facilitate continuation of MOUD in the community on release. The Massachusetts Justice Community Opioid Innovation Network (MassJCOIN) partnered with these seven diverse jails, the MA Department of Public Health, and community treatment providers to conduct a Type 1 hybrid effectiveness-implementation study of Chapter 208. We will: (1) Perform a longitudinal treatment outcome study among incarcerated individuals with OUD who receive NTX, BUP, methadone, or no MOUD in jail to examine postrelease MOUD initiation, engagement, and retention, as well as fatal and nonfatal opioid overdose and recidivism; (2) Conduct an implementation study to understand systemic and contextual factors that facilitate and impede delivery of MOUDs in jail and community care coordination, and strategies that optimize MOUD delivery in jail and for coordinating care with community partners; (3) Calculate the cost to the correctional system of implementing MOUD in jail, and conduct an economic evaluation from state policy-maker and societal perspectives to compare the value of MOUD prior to release from jail to no MOUD among matched controls. MassJCOIN made significant progress during its first six months until the COVID-19 pandemic began in March 2020. Participating jail sites restricted access for nonessential personnel, established other COVID-19 mitigation policies, and modified MOUD programming. MassJCOIN adapted research activities to this new reality in an effort to document and account for the impacts of COVID-19 in relation to each aim. The goal remains to produce findings with direct implications for policy and practice for OUD in criminal justice settings.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Buprenorphine; Criminal justice settings; MOUD; Massachusetts Justice Community Opioid Innovation Network (MassJCOIN); Medications for opioid use disorder; Methadone; Naltrexone; Opioid use disorder; Research protocol

Mesh:

Substances:

Year:  2021        PMID: 33483222      PMCID: PMC8263807          DOI: 10.1016/j.jsat.2021.108275

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  24 in total

1.  Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions.

Authors:  Peter D Friedmann; Randall Hoskinson; Michael Gordon; Robert Schwartz; Timothy Kinlock; Kevin Knight; Patrick M Flynn; Wayne N Welsh; Lynda A R Stein; Stanley Sacks; Daniel J O'Connell; Hannah K Knudsen; Michael S Shafer; Elizabeth Hall; Linda K Frisman
Journal:  Subst Abus       Date:  2012       Impact factor: 3.716

2.  Monetary conversion factors for economic evaluations of substance use disorders.

Authors:  Kathryn McCollister; Xuan Yang; Bisma Sayed; Michael T French; Jared A Leff; Bruce R Schackman
Journal:  J Subst Abuse Treat       Date:  2017-07-18

3.  The benefits and implementation challenges of the first state-wide comprehensive medication for addictions program in a unified jail and prison setting.

Authors:  Lauren Brinkley-Rubinstein; Meghan Peterson; Jennifer Clarke; Alexandra Macmadu; Ashley Truong; Kimberly Pognon; Morgan Parker; Brandon D L Marshall; Traci Green; Rosemarie Martin; Lynda Stein; Josiah D Rich
Journal:  Drug Alcohol Depend       Date:  2019-10-07       Impact factor: 4.492

4.  Initiation of buprenorphine during incarceration and retention in treatment upon release.

Authors:  Nickolas Zaller; Michelle McKenzie; Peter D Friedmann; Traci C Green; Samuel McGowan; Josiah D Rich
Journal:  J Subst Abuse Treat       Date:  2013-03-27

5.  Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial.

Authors:  Stephen Magura; Joshua D Lee; Jason Hershberger; Herman Joseph; Lisa Marsch; Carol Shropshire; Andrew Rosenblum
Journal:  Drug Alcohol Depend       Date:  2008-10-18       Impact factor: 4.492

6.  Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo; Ken Bachrach; Genie L Bailey; Snehal Bhatt; Sarah Farkas; Marc Fishman; Phoebe Gauthier; Candace C Hodgkins; Jacquie King; Robert Lindblad; David Liu; Abigail G Matthews; Jeanine May; K Michelle Peavy; Stephen Ross; Dagmar Salazar; Paul Schkolnik; Dikla Shmueli-Blumberg; Don Stablein; Geetha Subramaniam; John Rotrosen
Journal:  Lancet       Date:  2017-11-14       Impact factor: 79.321

Review 7.  Developing an opioid use disorder treatment cascade: A review of quality measures.

Authors:  Arthur Robin Williams; Edward V Nunes; Adam Bisaga; Harold A Pincus; Kimberly A Johnson; Aimee N Campbell; Remien H Remien; Stephen Crystal; Peter D Friedmann; Frances R Levin; Mark Olfson
Journal:  J Subst Abuse Treat       Date:  2018-06-02

8.  Estimated Prevalence of Opioid Use Disorder in Massachusetts, 2011-2015: A Capture-Recapture Analysis.

Authors:  Joshua A Barocas; Laura F White; Jianing Wang; Alexander Y Walley; Marc R LaRochelle; Dana Bernson; Thomas Land; Jake R Morgan; Jeffrey H Samet; Benjamin P Linas
Journal:  Am J Public Health       Date:  2018-10-25       Impact factor: 11.561

9.  Advancing theory on the multilevel role of leadership in the implementation of evidence-based health care practices.

Authors:  Erick G Guerrero; Jemima Frimpong; Yinfei Kong; Karissa Fenwick; Gregory A Aarons
Journal:  Health Care Manage Rev       Date:  2020 Apr/Jun

10.  COVID-19 and treating incarcerated populations for opioid use disorder.

Authors:  Christopher J Donelan; Edmond Hayes; Ruth A Potee; Levin Schwartz; Elizabeth A Evans
Journal:  J Subst Abuse Treat       Date:  2020-12-02
View more
  4 in total

1.  Legislatively mandated implementation of medications for opioid use disorders in jails: A qualitative study of clinical, correctional, and jail administrator perspectives.

Authors:  Ekaterina Pivovarova; Elizabeth A Evans; Thomas J Stopka; Claudia Santelices; Warren J Ferguson; Peter D Friedmann
Journal:  Drug Alcohol Depend       Date:  2022-03-07       Impact factor: 4.852

2.  Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail.

Authors:  Elizabeth A Evans; Ekaterina Pivovarova; Thomas J Stopka; Claudia Santelices; Warren J Ferguson; Peter D Friedmann
Journal:  J Subst Abuse Treat       Date:  2022-02-23

3.  Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder.

Authors:  Elizabeth A Evans; Donna Wilson; Peter D Friedmann
Journal:  Drug Alcohol Depend       Date:  2022-01-18       Impact factor: 4.492

Review 4.  Scoping review of mental health in prisons through the COVID-19 pandemic.

Authors:  Luke Johnson; Kerry Gutridge; Julie Parkes; Anjana Roy; Emma Plugge
Journal:  BMJ Open       Date:  2021-05-13       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.